Copyright
©The Author(s) 2012.
世界华人消化杂志. 2012-11-18; 20(32): 3140-3153
在线出版 2012-11-18. doi: 10.11569/wcjd.v20.i32.3140
在线出版 2012-11-18. doi: 10.11569/wcjd.v20.i32.3140
第一作者 | 发表年份 | 国家 | 放疗方案 | 化疗方案 | 放化疗顺序 | 病理类型 | 临床分期 | 分组 | 人数(n) | 男/女(n) | 中位年龄(yr) | 中位生存期(mo) | 中位随访期(mo) | Jadad评分[4] |
Nygaard等[5] | 1992 | Norway | 35 Gy, 1.75 Gy per fraction over 4 wk | Two cycles: cisplatin 20 mg/m2 d1-5; bleomycin 5 mg/m2 1-5 d | Sequential | SCC | T1 or T2, Nx, M0 | CRTS | 47 | 33/14 | 60.1 | 7 | 18 | 2 |
SA | 41 | 31/10 | 61.4 | 7 | ||||||||||
Apinop等[6] | 1994 | Thailand | 40 Gy, 2 Gy per fraction over 4 wk | Two cycles: cisplatin 100 mg/m2 1 d; fluorouracil 1000 mg/m2 1-4 d | Concurrent | SCC | IIb(11); III(57) | CRTS | 35 | 28/7 | 59.6 | 9.7 | 12 | 1 |
SA | 34 | 26/8 | 59.8 | 7.4 | ||||||||||
Le Prise等[7] | 1994 | France | 40 Gy, 20 Gy in 10 fractions over 12 d | Two cycles: cisplatin 100 mg/m2 d1, 21; fluorouracil 600 mg/m2 2-5 d, 22-25 d | Sequential | SCC | I(23); II(63) | CRTS | 41 | 80/6 | 56 | 10.2 | 16 | 2 |
SA | 45 | 59 | 11 | |||||||||||
Walsh等[8] | 1996 | Ireland | 40 Gy in 15 fractions over 3 wk | Two cycles: cisplatin 75 mg/m2 1 d; fluorouracil 15 mg/kg 1-5 d | Concurrent | AC | not distant metastases | CRTS | 58 | 39/19 | 65 | 16 | 10 | 2 |
SA | 55 | 44/11 | 65 | 11 | ||||||||||
Bosset等[9] | 1997 | France | 37 Gy, 3.7 Gy per fraction over 2 wk | Two cycles: cisplatin 80 mg/m2 0-2 d | Sequential | SCC | T1N0(49); T2N0(92); T3N0(76); T1N1 or T2N1(65) | CRTS | 143 | 129/14 | 56.7 | 18.6 | 55.2 | 3 |
SA | 139 | 134/5 | 56.6 | 18.6 | ||||||||||
Urba等[10] | 2001 | USA | 45 Gy; 1.5 Gy per fraction over 3 wk | Two cycles: cisplatin 20 mg/m2 1-5 d; fluorouracil 300 mg/m2 1-21 d; vinblastine 1 mg/m2 1-4 d | Concurrent | SCC(25%); AC(75%) | not distant metastases | CRTS | 50 | 42/8 | 62 | 16.9 | 98.4 | 2 |
SA | 50 | 43/7 | 64 | 17.6 | ||||||||||
安丰山等[11] | 2003 | China | 36 Gy, 1.2 Gy per fraction over 17 d | First cycle: 5-fluorouracil 1 mg/m2, 5-6 h, 1-5 d; cisplatin 25 mg/m2. | Sequential | SCC | II, III | CRTS | 48 | 31/17 | 58.4 | 42 | 34.12 | 3 |
SA | 50 | 47/3 | 63 | 27.3 | ||||||||||
第一作者 | 发表 年份 | 国家 | 放疗方案 | 化疗方案 | 放化疗顺序 | 病理类型 | 临床分期 | 分组 | 人数(n) | 男/女 (n) | 中位年 龄(yr) | 中位生 存期(mo) | 中位随 访期(mo) | Jadad 评分[4] |
Nygaard等[5] | 1992 | Norway | 35 Gy, 1.75 Gy per fraction over 4 wk | Two cycles: cisplatin 20 mg/m2 d1-5; bleomycin 5 mg/m2 1-5 d | Sequential | SCC | T1 or T2, Nx, M0 | CRTS | 47 | 33/14 | 60.1 | 7 | 18 | 2 |
SA | 41 | 31/10 | 61.4 | 7 | ||||||||||
Apinop等[6] | 1994 | Thailand | 40 Gy, 2 Gy per fraction over 4 wk | Two cycles: cisplatin 100 mg/m2 1 d; fluorouracil 1000 mg/m2 1-4 d | Concurrent | SCC | IIb(11); III(57) | CRTS | 35 | 28/7 | 59.6 | 9.7 | 12 | 1 |
SA | 34 | 26/8 | 59.8 | 7.4 | ||||||||||
Le Prise等[7] | 1994 | France | 40 Gy, 20 Gy in 10 fractions over 12 d | Two cycles: cisplatin 100 mg/m2 d1, 21; fluorouracil 600 mg/m2 2-5 d, 22-25 d | Sequential | SCC | I(23); II(63) | CRTS | 41 | 80/6 | 56 | 10.2 | 16 | 2 |
SA | 45 | 59 | 11 | |||||||||||
Walsh等[8] | 1996 | Ireland | 40 Gy in 15 fractions over 3 wk | Two cycles: cisplatin 75 mg/m2 1 d; fluorouracil 15 mg/kg 1-5 d | Concurrent | AC | not distant metastases | CRTS | 58 | 39/19 | 65 | 16 | 10 | 2 |
SA | 55 | 44/11 | 65 | 11 | ||||||||||
Bosset等[9] | 1997 | France | 37 Gy, 3.7 Gy per fraction over 2 wk | Two cycles: cisplatin 80 mg/m2 0-2 d | Sequential | SCC | T1N0(49); T2N0(92); T3N0(76); T1N1 or T2N1(65) | CRTS | 143 | 129/14 | 56.7 | 18.6 | 55.2 | 3 |
SA | 139 | 134/5 | 56.6 | 18.6 | ||||||||||
Urba等[10] | 2001 | USA | 45 Gy; 1.5 Gy per fraction over 3 wk | Two cycles: cisplatin 20 mg/m2 1-5 d; fluorouracil 300 mg/m2 1-21 d; vinblastine 1 mg/m2 1-4 d | Concurrent | SCC(25%); AC(75%) | not distant metastases | CRTS | 50 | 42/8 | 62 | 16.9 | 98.4 | 2 |
SA | 50 | 43/7 | 64 | 17.6 | ||||||||||
安丰山等[11] | 2003 | China | 36 Gy, 1.2 Gy per fraction over 17 d | First cycle: 5-fluorouracil 1 mg/m2, 5-6 h, 1-5 d; cisplatin 25 mg/m2. | Sequential | SCC | II, III | CRTS | 48 | 31/17 | 58.4 | 42 | 34.12 | 3 |
Second cycle: 5-fluoro- uracil 0.5 g/m2, 21-25 d; cisplatin 25 mg/m2, 22-25 d | SA | 49 | 30/19 | 57.6 | 28 | |||||||||
Lee等[12] | 2004 | Korea | 45.6 Gy, 1.2 Gy per fraction over 28 d | Two cycles: cisplatin 60 mg/m2 d1; fluorouracil 1000 mg/m2 3-5 d | Concurrent | SCC | IIA(36); IIB(22); III(43); N0(36); N1(65) | CRTS | 51 | 46/5 | 63 | 28.2 | 25 | 2 |
Burmeister 等[13] | 2005 | Australia | 35 Gy in 15 fractions over 3 wk | One cycles: cisplatin 80 mg/m2 d1; fluorouracil 800 mg/m2 1-4 d | Concurrent | SCC(37%); AC(62%) | T1-3, N0-1 | CRTS | 128 | 106/22 | 61 | 22.2 | 65 | 3 |
SA | 128 | 100/28 | 62 | 19.3 | ||||||||||
Natsugoe 等[14] | 2006 | Japan | 40 Gy, 2 Gy per fraction over 4 wk | cisplatin 7 mg over 2 h; 5-fluorouracil 350 mg over 24 h | Concurrent | SCC | II(9); III(24); IV(12) | CRTS | 22 | - | - | - | 24 | 2 |
SA | 23 | - | - | - | ||||||||||
Tepper等[15] | 2008 | USA | 50.4 Gy, 1.8 Gy per fraction over 5.6 wk | Two cycles: cisplatin 100 mg/m2 1 d; fluorouracil 1 000 mg/(m2·d ) 1-4 d | Concurrent | SCC(25%); AC(75%) | T1-3, Nx | CRTS | 30 | 28/2 | 59.9 | 53.76 | 72 | 2 |
SA | 26 | 23/3 | 62.2 | 21.48 | ||||||||||
彭林等[16] | 2008 | China | 40 Gy, 2 Gy per fraction over 4 wk | Two cycles: cisplatin 75 mg/m2 1 d; 5-fluorouracil 500 mg/m2 over 5d | Concurrent | SCC | IIB; III | CRTS | 40 | 30/40 | 58.4 | 30 | 37.5 | 3 |
SA | 40 | 32/8 | 57.5 | 24 | ||||||||||
金明根等[17] | 2008 | China | 38-44 Gy, 2 Gy per fraction, total 19-22 fractions | Paclitaxe 135 mg/m2, 1 d,22; cisplatin 20-30 mg/m2, dl-5, 22-26 d | Concurrent | SCC(92%); AC(8%) | II(26); III(36) | CRTS | 30 | 22/8 | 49 | - | - | 3 |
SA | 30 | 20/10 | - | |||||||||||
Cao等[18] | 2009 | China | 40 Gy, 2 Gy per fraction over 4 wk | cisplatin 20 mg/(m2·d) ds1-5; fluorouracil 500 mg/(m2·d) 1-5 d; mitomycin 10 mg/(m2·d) 1 d | Concurrent | SCC | II(15); III(211); IV(10) | CRTS | 118 | 60/58 | - | 59 | - | 2 |
SA | 118 | 67/51 | - | 43 | ||||||||||
吕进等[19] | 2009 | China | 40 Gy, 2 Gy/d, 1-5 d, 8-12, 15-19, 22-26 | Two cycles: Paclitaxe 125 mg/m2, l d; | Concurrent | SCC | IIb(15); III(213); IV(10) | CRTS | 119 | 61/58 | - | 30.5 | - | 2 |
cisplatin 20 mg/m2, 1-3 d | SA | 119 | 68/51 | - | 18.3 | |||||||||
Lv等[20] | 2010 | China | 40 Gy, 2 Gy per fraction over 4 wk | Two cycles: cisplatin 20 mg/(m2·d), 1-3 d, 22-25; paclitaxel 135 mg/m2 starting on 1 d, 22 of radiotherapy | Concurrent | SCC | II(71); III(89) | CRTS | 80 | 52/28 | - | 53 | 45 | 2 |
SA | 80 | 50/30 | - | 36 | ||||||||||
谢军等[21] | 2010 | China | 45-5l Gy, 2 Gy per faction, 1-5 d/wk, total 2l-25 fractions | 5-fluorouracil 2.4 g/m2 l-3 d, 22-24; cisplatin 75 mg/m2, 1 d, 22 | Concurrent | SCC | II(22); III(47); IVa(1) | CRTS | 35 | 27/8 | 50 | - | - | 3 |
SA | 35 | 25/10 | - | |||||||||||
张文山等[22] | 2011 | China | 40 Gy, 1.8-2.0 Gy per fraction over 4 wk | Two cycles 5-fluorouracil 500 mg/m2, 1-5 d; cisplatin 30 mg/(m2·d) | Concurrent | - | III | CRTS | 29 | 18/11 | 50.4 | 40 | - | 3 |
SA | 40 | 26/14 | 52.2 | 29 | ||||||||||
金芳玲等[23] | 2011 | China | 50 Gy, 2 Gy per fraction over 5 wk mg/(m2·d), 1-5 d | Two cycles: cisplatin 75 mg/(m2·d), d1; 5-fluorouracil 500 mg/(m2·d), 1-5 d | Concurrent | SCC(92%); AC(8%) | IIa(10); IIb(9); III(41) | CRTS | 30 | 18/12 | 54 | 34 | - | 2 |
SA | 30 | 21/9 | 22 | |||||||||||
van Hagen 等[24] | 2012 | Netherlands | 41.4 Gy, 1.8 Gy per fraction over 4.6 wk | 5 wk chemotherapy; carboplatin area under curve = 2 and paclitaxel 50 mg/m2 on 1 d weekly | Concurrent | SCC(23%); AC(75%) | T1N1 or T2-3N0-1M0 | CRTS | 178 | 134/44 | 60 | 49.4 | 45.4 | 2 |
SA | 188 | 152/26 | 60 | 24 | ||||||||||
杨弘等[25] | 2012 | China | 40 Gy, 2 Gy per fraction over 4 wk | Two cycles: navelbine 25 mg/m2 1,8,22,29 d;cisplatin 75 mg/m2 1,22 d | Concurrent | SCC | IIB(20) III(113) | CRTS | 54 | 46/8 | 54 | - | - | 3 |
引文著录: 王亚梅, 王峰, 何炜, 樊青霞. 术前放化疗与单纯手术治疗可切除食管癌的Meta分析. 世界华人消化杂志 2012; 20(32): 3140-3153